The standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy [5] followed by maintenance therapy with the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab [6]. Here, CD274 is linked to non-small cell lung carcinoma.